Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Chemoprevention using dutasteride: the REDUCE trial.

Leonard G Gomella1

  • 1Department of Urology, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA.

Current Opinion in Urology
|December 9, 2004
PubMed
Summary

The REDUCE trial investigates dutasteride, a dual 5alpha-reductase inhibitor, for prostate cancer chemoprevention. Building on finasteride trial success, it targets high-risk men to assess dutasteride

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ten Years of Progress in Advanced Prostate Cancer at the AUA.

The Canadian journal of urology·2026
Same author

Future opportunities and nuances with the use of PSMA PET in prostate cancer (MD PET 1).

Theranostics·2026
Same author

The Effects of Bone-Remodeling Therapy on Survival, Pain, and Skeletal Related Events in the Setting of Renal Cell Carcinoma With Bone Metastases: A Multicenter Investigation From a Large Global Health Research Network (TriNetX).

Cancer medicine·2026
Same author

Evaluating the impact of a community-based prostate cancer screening program.

Archives of public health = Archives belges de sante publique·2025
Same author

Patient-Reported Outcomes From Males Regarding Germline Testing for Prostate Cancer: Results From the PROGRESS Registry.

JCO precision oncology·2025
Same author

PARP inhibitors elicit distinct transcriptional programs in homologous recombination competent castration-resistant prostate cancer.

Molecular oncology·2025

Area of Science:

  • Oncology
  • Pharmacology
  • Men's Health

Background:

  • The Prostate Cancer Prevention Trial (PCPT) demonstrated finasteride's efficacy in reducing prostate cancer prevalence by approximately 25%.
  • Finasteride selectively inhibits type 2 5alpha-reductase, while dutasteride inhibits both type 1 and type 2 isoforms.
  • Increased type 1 5alpha-reductase expression in prostate cancer suggests dutasteride as a potential chemopreventive agent.

Purpose of the Study:

  • To review the design and rationale of the Reduction by Dutasteride of Prostate Cancer Events (REDUCE) trial.
  • To contextualize the REDUCE trial within the findings of the completed Prostate Cancer Prevention Trial.
  • To evaluate dutasteride as a chemoprevention strategy for prostate cancer.

Main Methods:

  • The REDUCE trial employs a chemoprevention strategy using dutasteride.

Related Experiment Videos

  • Participants are men identified as having an increased risk of developing prostate cancer.
  • The trial is designed to determine the effectiveness of dutasteride in this high-risk population.

    • Main Results:

    • The PCPT established proof of principle for 5alpha-reductase inhibitors in prostate cancer chemoprevention.
    • A nearly 25% reduction in prostate cancer prevalence was observed with finasteride compared to placebo.
    • Dutasteride's dual inhibition mechanism is being investigated for enhanced efficacy.

    Conclusions:

    • Chemoprevention using 5alpha-reductase inhibitors is a viable strategy for prostate cancer.
    • The REDUCE trial aims to confirm dutasteride's effectiveness in preventing prostate cancer in at-risk men.
    • Hormonal agents show promise for future prostate cancer prevention protocols.